27 August 2020

Much research has been done on the effectiveness and safety of systemic antipsoriasis therapies in general, but the effectiveness in specifically older adults psoriasis patients has never been systematically assessed. 

Led by Satish Lubeek of the Department of Dermatology (photo), physician-researchers Marieke van Winden and Lara van der Schoot - together with other researchers - have conducted research into the effectiveness and safety of systemic anti-psoriasis therapies in patients over 65 years of age.


It seems that the effectiveness of treatment with acitretin, etanercept, adalimumab and secukinumab is not affected by advanced age. Studies of other systemic anti-psoriasis drugs have not made age group comparisons. Older age was significantly associated with impairment of renal function in users of ciclosporin and lymphopenia in users of fumaric acid. Infections were the most frequently reported side effect in patients over 65 years of age using biologics; no significant association with age was found.

Conclusions and relevance

Based on the very limited relevant studies available, age alone should not be a limiting factor in the treatment of psoriasis. Awareness of other medical conditions and concomitant medication use is very important in older adults, as well as possible dosage adjustments and frequent laboratory and clinical monitoring.
More research from daily practice, as well as (sub)analyses of prospective cohort studies on the effectiveness and safety of systemic therapies in older adults, are crucial for optimizing personalized, effective and safe anti-psoriasis treatments in this growing patient group.

The research was recently published in the scientific medical journal Journal of the American Medical Association: Jama Dermatology. It is also discussed in the corresponding editorial.

Related news items

Recognition & Rewards: panel discussion 20 October 2021

11 October 2021

What makes a good researcher? How should we evaluate and reward good academic practices? What metrics, if any, should we use to evaluate university staff and award funding? Could deviating from current international standards be good or bad for Dutch academia?

read more

Palliative care for people with Parkinson’s Disease and their family Caregivers Current state of affairs

7 October 2021

Advanced stage Parkinson’s disease can cause a variety of symptoms, for which palliative care can be beneficial, though research from the point of view of patients in later stages is still rare. Radboudumc researchers therefore placed their patients perspectives at the center of their recent study.

read more

AI helps the defibrillator think

4 October 2021

In the future, the AED and the defibrillator will be able to do more than they do today. Now the devices can only give patients who need to be resuscitated a shock, but in time it will be possible, with the help of artificial intelligence, to say more about the condition of the patient.

read more

Do you want to participate in producing a short film about your PhD research?

28 September 2021

In the new BMS master course 'Moving Science - using film in science communication', master students will make a short film about a scientific subject. And what is better a subject than your PhD project? Sign up here!

read more

Antibodies are sustained in nasal fluid after mild corona infection

27 September 2021

Testing through nasal fluids is easier than through blood

read more

Large AI project receives over €95 million for ten years of public-private research

23 September 2021

The Dutch Research Council (NWO) is to fund two consortia for a period of ten years. Radboudumc participates in the ROBUST consortium, which consists of 17 AI labs, eight of which are dedicated to healthcare. Radboudumc leads five of these eight labs.

read more